TC BioPharm (Holdings) plc
TCB, based in Scotland, is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections.
TCB is embarking on Phase II-into-pivotal (Phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulations, with a view to launching its first oncology product, which will be for the treatment of acute myeloid leukemia (abbreviated as AML). The Company plans to conduct similar clinical trials in the United States in 2022 for the treatment of AML following an application to the FDA in H1 2022. Clinical results generated thus far have enabled TCB to obtain FDA orphan drug status for its method of treatment of AML.
In addition to unmodified allogenic GD-Ts for treatment of blood cancers, TCB is also developing an innovative range of genetically modified chimeric antigen receptor modified T cell (abbreviated as CAR-T) products for treatment of solid cancers. TCB believes that solid cancers are more difficult to treat than blood cancers and may require addition of a chimeric antigen receptor (abbreviated as CAR) to (i) help therapeutic cells ‘navigate’ into diseased cancerous tissue, and (ii) retain therapeutic cells in-situ at the lesion for maximum efficacy.
In response to the recent pandemic, because GD-Ts are natural killers of virally infected cells, as well as cancerous cells, TCB is planning clinical studies to treat patients with both acute and long term COVID-19 symptoms. We believe acute COVID-19 trials will start in the fourth quarter of 2021.
(Note: TC BioPharm upsized its unit IPO at pricing on Feb. 10, 2022, to 4.12 million American Depositary Shares (ADS) and warrants to buy up to 8.24 million ADS – priced at $4.25 per unit – to raise $17.5 million. Each unit consists of one ADS and two warrants. The pricing marked an increase in the number of ADS to 4.12 million from 3.76 million in the amended prospectus filed with the SEC on Feb. 9, 2022.The deal’s terms had been cut three times since October 2021, SEC records showed.)
|Industry:||Cell therapy - immunotherapies|
|Address||Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdom|
|Phone Number||+44 (0) 141 433 7557|
|View Prospectus:||TC BioPharm (Holdings) plc|
|Revenues||$3.0 mil (last 12 months)|
|Net Income||$-14.89 mil (last 12 months)|
|Price range||$4.25 - $4.25|
|Est. $ Volume||$17.5 mil|
|Manager / Joint Managers||EF Hutton|
|Expected To Trade:||2/11/2022|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|